-
Article
Open AccessPeritumoral edema status of glioblastoma identifies patients reaching long-term disease control with specific progression patterns after tumor resection and high-dose proton boost
Glioblastoma peritumoral edema (PE) extent is associated with survival and progression pattern after tumor resection and radiotherapy (RT). To increase tumor control, proton beam was adopted to give high-dose ...
-
Article
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR
Telomerase reverse transcriptase promoter (TERTp) hotspot mutations are the most frequent mutations in primary glioblastomas (GBM). Previous studies have shown that the combination of TERTp and isocitrate dehydro...
-
Article
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells
Although chemoimmunotherapy often lengthens glioblastoma (GBM) survival, early relapses remain problematic as immunosuppressive M2 macrophages (Mϕ) that function via inhibitory cytokine and PD-L1 production ca...
-
Article
Open AccessEarly clinical experience utilizing scintillator with optical fiber (SOF) detector in clinical boron neutron capture therapy: its issues and solutions
Real-time measurement of thermal neutrons in the tumor region is essential for proper evaluation of the absorbed dose in boron neutron capture therapy (BNCT) treatment. The gold wire activation method has been...
-
Article
Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas
The molecular subgrou** of diffuse gliomas was recently found to stratify patients into prognostically distinct groups better than histological classification. Among several molecular parameters, the key mol...
-
Article
Rosette-forming glioneuronal tumor originating in the hypothalamus
Rosette-forming glioneuronal tumors (RGNT) of the fourth ventricle are slow-growing tumors that primarily involve the fourth ventricular region. We here report the first patient, an 8-year-old girl, with an RG...
-
Article
Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas
Isocitrate dehydrogenase (IDH) mutation is a valuable prognostic marker and a tool for decision-making for glioma treatment. An algorithm for IDH mutation screening was recently proposed—it consists of a two-s...
-
Article
Preface to special edition
-
Article
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind
The present retrospective data analysis was performed to determine whether intraoperative pathological diagnosis (IOD) using frozen section (FS) could clearly distinguish high-grade glioma from WHO grade II gl...
-
Article
Comparison of magnetic resonance imaging with invasive histological findings of Langerhans cell histiocytosis
Due to the rarity of skull Langerhans cell histiocytosis (LCH), correlations between abnormalities on magnetic resonance imaging (MRI) and pathological findings have not been fully evaluated. Only a few report...
-
Article
Benign spinal meningioma without dural attachment presenting delayed CSF dissemination and malignant transformation
Benign spinal meningiomas have good prognoses, with low rates of recurrence and no cerebrospinal fluid (CSF) dissemination. However, we experienced an extremely rare case of initially benign non-dura-based spi...
-
Article
Erratum to: Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
-
Article
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
Isocitrate dehydrogenase 1 (IDH1) mutations have recently been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as secondary glioblastoma...
-
Chapter
Malignant Brain Tumors: Role of Radioresponsive Gene Therapy
Patients with malignant gliomas have a very poor prognosis. To explore a novel and more effective approach for the treatment of malignant gliomas, a strategy combining suicide gene therapy and radiation treatm...
-
Article
Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity
Although antiangiogenic treatment for malignant glioma using bevacizumab in combination with irinotecan chemotherapy has a promising effect on survival, the high incidence of increasing infiltrative tumors can...
-
Article
Epileptogenic glioma in a 4-year-old child: a case report
We report a rare case of epileptogenic glioma composed of glial progenitor cells that differentiated into an astrocytic and oligodendrocytic tumor. This 4-year-old girl presented with a 1-year history of compl...
-
Article
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells
Inhibition of angiogenesis is an important new treatment modality for malignancies, including gliomas. Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α (HIF-1α) have been investigated...
-
Article
Angiogenesis and antiangiogenic therapy for malignant gliomas
Angiogenesis is crucial to the growth of malignant gliomas. Therefore, antiangiogenic therapy represents a new, promising therapeutic modality for malignant gliomas. This study was designed to define the malig...
-
Article
Localization of gelatinase activities in glioma tissues by film in situ zymography
Malignant gliomas are characterized by their invasiveness and angiogenesis, which are mediated by metalloproteinases (MMPs). In this study, localization of gelatinase activities in six cases of glioblastoma, t...
-
Chapter
Clinical Protocol Using New Neutron Irradiation Facility (JRR4) at JAERI
After the shutdown of the former JRR2, which had been used for boron neutron capture therapy (BNCT) in clinical cases, in summer 1998 a new neutron irradiation facility (JRR4) was installed as a medical reacto...